Multiple myeloma cell therapy Abecma is the lone remaining asset of 2seventy Bio, which spun out from Bluebird Bio ...

Bristol Myers Squibb will acquire 2seventy bio for about $286 million in cash, sending the cancer cell therapy maker's shares ...

Bristol-Myers Squibb acquires 2seventy bio for $286M, marking the end of a once-promising biotech. Check out if this is a ...

(NASDAQ:TSVT) shares popped nearly 4% premarket on Tuesday after it entered a deal to be acquired by Bristol Myers Squibb ...

CAMBRIDGE, Mass., March 11, 2025--2seventy bio, Inc. (Nasdaq: TSVT), today announced a definitive merger agreement under ...

The deal ends 2Seventy’s short run as an independent company, during which it restructured, sold off research and lost nearly ...

Bio (TSVT) announced a definitive merger agreement under which Bristol Myers Squibb (BMY) will acquire all of the outstanding shares ...

More than a year into a strategic pivot to zero in on the multiple myeloma cell therapy Abecma, 2seventy bio is selling ...

Bristol Myers Squibb to acquire 2seventy Bio for $5.00 per share in a $286 million all-cash deal, an 88% premium to its last ...

Bristol Myers Squibb buys 2seventy bio for $286 million, strengthening its cancer portfolio with Abecma CAR-T therapy for ...

Shares of 2seventy bio took flight Tuesday after the biotechnology company agreed to be acquired by partner Bristol Myers Squibb. Bristol Myers is paying $5 a share in cash for 2seventy, a 79% premium ...

The Ademi Firm is investigating 2seventy bio (Nasdaq: TSVT) for possible breaches of fiduciary duty and other violations of ...